This is happening at a time of conservatism toward gene therapy in the United States. Investment in the U.S. slowed after an 18-year-old Pennsylvania boy died in a gene therapy trial seven years ago. His parents filed a lawsuit. The Food and Drug Administration put other trials on hold.
…
Patients in China are less likely to file lawsuits, and Chermak says Chinese regulators are more open-minded to new treatments. They see the slowdown in the United States as an opportunity to get ahead.

At the same time, a lot of Chinese researchers who studied in the U.S. are returning home because in China, you can get much more bang for your research buck.